Dr Reddy’s And BMS Shake Hands On Pomalyst Settlement
Final Judgment Says Reddy’s Does Not Infringe Key Drug Substance Patent
Bristol Myers Squibb does not “expect generic entry in the US market prior to the first quarter of 2026” for its Pomalyst treatment for relapsed and refractory multiple myeloma, after reaching a settlement agreement with ANDA sponsor Dr Reddy’s Laboratories.
